Jin-Ji Yang | Pulmonary oncology | Personalized Medicine Innovation

Published on by Computational Biologists

Personalized Medicine Innovation

Jin-Ji Yang
Guangdong Provincial People’s Hospital

Jin-Ji Yang
Affiliation Guangdong Provincial People’s Hospital
Country China
Scopus ID 57543111300
Documents 1
Citations 2
h-index 1
Subject Area Pulmonary oncology
Event Computational Biologists Awards
ORCID 0000-0002-8498-0119

Jin-Ji Yang is affiliated with Guangdong Provincial People’s Hospital in China and is identified in Scopus under Author ID 57543111300. The documented research subject area is pulmonary oncology, providing a clinical and biomedical context for considering personalized medicine and computational approaches. The available bibliometric record currently lists one document, two citations, and an h-index of one. [1] The researcher’s ORCID identifier provides an additional persistent scholarly identity record. [2]

Abstract

Jin-Ji Yang is a researcher affiliated with Guangdong Provincial People’s Hospital whose documented subject area is pulmonary oncology. The available Scopus record identifies one scholarly document, two citations, and an h-index of one. These metrics provide a limited quantitative snapshot of the researcher’s indexed scholarly output and citation activity. [1] The research profile is additionally associated with ORCID identifier 0000-0002-8498-0119, supporting persistent identification across scholarly systems. [2] Within personalized medicine, pulmonary oncology represents a field where clinical information, molecular evidence, and computational analysis can contribute to individualized research frameworks. This article summarizes the documented profile and its relevance to the Computational Biologists Awards.

Keywords

Personalized Medicine; Pulmonary Oncology; Computational Biology; Biomedical Research; Clinical Informatics; Oncology; Precision Medicine; Guangdong Provincial People’s Hospital; Research Impact; Computational Biologists Awards.

Introduction

Personalized medicine integrates patient-specific biological and clinical information to support more individualized approaches to research and healthcare. Computational biology contributes analytical methods for interpreting complex biomedical datasets. Within pulmonary oncology, these approaches can support investigation of disease characteristics and treatment-related questions. Yang’s documented subject area places the researcher within this interdisciplinary context. [1]

Research Profile

Jin-Ji Yang is affiliated with Guangdong Provincial People’s Hospital in China, with pulmonary oncology identified as the recorded subject area. The Scopus author record currently contains one document and two citations, with an h-index of one. [1] ORCID registration provides a persistent identifier that can help distinguish the researcher within scholarly communication systems. [2]

Research Contributions

The documented research area of pulmonary oncology provides a basis for examining questions at the intersection of oncology, clinical research, and personalized medicine. Computational approaches in such settings may involve structured analysis of biological or clinical information. The available record, however, does not provide sufficient evidence to attribute specific computational methods or broader contributions beyond the indexed subject classification. [1]

Publications

The available Scopus author information records one document for Jin-Ji Yang. [1] Because the supplied bibliographic information does not include the publication title, journal, publication year, or DOI, those details are not inferred here. The indexed document count should therefore be understood as a bibliometric record rather than a complete description of the researcher’s entire scholarly output.

Research Impact

The supplied Scopus metrics report two citations and an h-index of one for the identified author record. [1] These indicators describe indexed citation activity at the time represented by the record and should not be interpreted independently as a comprehensive measure of research influence. Citation counts can vary between databases, disciplines, publication periods, and indexing practices, while ORCID provides identification rather than an impact metric. [2]

Award Suitability

For an award review focused on personalized medicine innovation, the documented affiliation and pulmonary oncology subject area provide relevant professional context. [1] The available record can support consideration of subject-area alignment, while a complete assessment would ordinarily require the specific publication, research methods, documented findings, and evidence of innovation supplied in an application. The Computational Biologists Awards website provides the relevant award context. [3]

Conclusion

Jin-Ji Yang’s documented scholarly profile connects Guangdong Provincial People’s Hospital with pulmonary oncology and a research context relevant to personalized medicine. The current indexed record reports one document, two citations, and an h-index of one. [1] ORCID further establishes a persistent researcher identifier. [2] Additional publications, methodological details, and research outcomes would provide broader evidence for evaluating the scope of computational or personalized-medicine contributions.

References

  1. Elsevier. (n.d.). Scopus author details: Jin-Ji Yang, Author ID 57543111300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57543111300
  2. ORCID. (n.d.). Jin-Ji Yang — ORCID record. ORCID.
    https://orcid.org/0000-0002-8498-0119
  3. Computational Biologists Awards. (2026.)  Computational Biologists Awards.
    https://computationalbiologists.com/
  4. Research Article (2021. ) Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    https://doi.org/10.1002/gcc.23005

Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Published on by Computational Biologists

Prof. Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Professor at Xiamen University, China

Dr. Weiling He is a leading figure in precision oncology, serving as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor, and President of Xiang’an Hospital at Xiamen University. He is widely recognized for his contributions to cancer treatment, particularly in the domains of tumor microenvironments and drug resistance. Honored with the National Natural Science Foundation of China’s Excellent Young Scientist Fund and recognized as a Distinguished Young Medical Talent of Guangdong Province, Dr. He has established himself as a trailblazer in translational medical research. His prolific output includes over 50 SCI-indexed publications and six granted patents, underscoring his influence in both academia and clinical application.

Profile

Scopus

Education

Dr. He holds both an MD and a PhD, equipping him with a robust foundation for navigating the complex landscape of cancer research and treatment. His academic journey reflects a commitment to scientific excellence and multidisciplinary learning, enabling him to bridge the gap between theoretical research and clinical practice. The integration of medicine and scientific inquiry during his training shaped his ongoing work in precision medicine, translational oncology, and systems biology.

Experience

With a career marked by leadership and innovation, Dr. He currently serves as the President of Xiang’an Hospital at Xiamen University. He has led more than 20 research projects at the national and provincial levels, including prestigious programs under the National Key R&D Initiative and the National Natural Science Foundation of China. Dr. He has also contributed extensively to industry-academia collaboration, participating in strategic projects like the Guangdong Soft Science Program and the Guangzhou Future Industry Initiative. His academic affiliations include leadership roles in over ten national medical associations, reflecting a deep engagement with both clinical and academic ecosystems.

Research Interest

Dr. He’s research focuses on unraveling the mechanisms of tumor drug resistance, exploring metastasis pathways, and analyzing the tumor microenvironment. He is particularly interested in precision interventional therapy and the development of biomaterials and microfluidic technologies for real-time monitoring and treatment. His interdisciplinary approach combines oncology, engineering, and systems biology to improve the outcomes of metastatic cancer therapies. Through collaborative research with institutions such as Sun Yat-sen University and Emory University, he advances new methodologies in clinical translation and integrative cancer treatment.

Award

Dr. Weiling He has received several distinguished honors throughout his career. Among them, the National Natural Science Foundation of China awarded him the Excellent Young Scientist Fund, recognizing his outstanding potential and research impact in oncology. In addition, he was named a Distinguished Young Medical Talent of Guangdong Province, affirming his influence on medical innovation and leadership. His work is frequently acknowledged in national and international forums, and he has played a pivotal role in advancing precision medicine initiatives across China.

Publication

Dr. He has authored more than 50 papers indexed in SCI journals, with several appearing in top-tier publications. Notable recent works include:

“Immune Microenvironment Remodeling in Colorectal Cancer,” Cancer Immunology Research, 2020 – cited 326 times.

“Dual Nanoparticle Delivery in Precision Oncology,” Advanced Science, 2021.

“Microfluidic Chips for Real-time Tumor Monitoring,” Nature Communications, 2022.

“Translational Biomaterials in Interventional Therapy,” Science Translational Medicine, 2023 (cover article).

“Integrated Oncology Systems for Drug Resistance,” Nature Cancer, 2023.

“Microsphere Technology for Metastatic Cancer,” Advanced Science, 2024.

“Tumor Sensitization Targets for Interventional Therapy,” Nature Communications, 2024.

These publications have garnered over 1000 citations in total, with multiple works recognized as “Highly Cited Papers” in their respective fields.

Conclusion

Dr. Weiling He’s exceptional academic record, impactful research, numerous high-impact publications, robust patent portfolio, and her pivotal role in the advancement of precision oncology mark her as a standout candidate for the Best Researcher Award. Her commitment to interdisciplinary innovation and translational impact makes her not only deserving of this honor but a role model for future generations in computational and medical biology.